

Prostaglandin E₁ protects bone marrow-derived mesenchymal stem cells against serum deprivation-induced apoptosis

KUAN ZENG¹, BAO PING DENG¹, HUI-QI JIANG¹, MENG WANG¹,
PING HUA¹, HONG-WU ZHANG², YU-BIN DENG² and YAN-QI YANG¹

¹Department of Cardiac Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510120;

²Research Center of Translational Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510080, P.R. China

Received March 12, 2014; Accepted December 9, 2014

DOI: 10.3892/mmr.2015.4176

Abstract. Mesenchymal stem cells (MSCs) have become a recent focus of experimental and clinical research regarding myocardial regeneration. However, the therapeutic potential of these cells is limited by poor survival. Prostaglandin E₁ (PGE₁) is known to have anti-inflammatory and anti-apoptotic effects on the myocardium. The aim of the present study was to determine whether PGE₁ could protect MSCs against serum deprivation (SD)-induced apoptosis. An SD model was used to induce apoptosis in MSCs *in vitro*. Apoptotic morphological changes were detected by Hoechst 33258 fluorescent nuclear staining; and Annexin V-fluorescein isothiocyanate/propidium iodide (PI) double staining and flow cytometry was used to quantify the rate of apoptosis. Western blot analysis was used to detect the expression levels of the apoptosis-associated proteins Bcl-2, Bax and caspase-3. The results of the present study demonstrated that SD induced apoptosis of MSCs, and that treatment with PGE₁ attenuated the morphological changes characteristic of apoptosis. Annexin V/PI staining showed that the rate of apoptosis gradually increased with the duration of ischemia. Furthermore, treatment with PGE₁ significantly reduced SD-induced apoptosis, decreased the protein expression levels of Bax and caspase-3, and increased the expression levels of Bcl-2. These data suggest that PGE₁ is able to influence the survival of MSCs under certain conditions. These results may aid in improving the therapeutic efficacy of MSC transplantation used to treat chronic ischemic heart disease.

Introduction

Ischemic heart disease is one of the most common diseases worldwide. The traditional treatment of ischemic heart disease includes the prevention of atherosclerosis, and revascularization of the coronary arteries; however, these strategies cannot reverse or repair myocardial necrosis. Heart transplantation is an effective treatment for patients with late-stage heart failure, however due to the insufficient supply of organs there are limits to its clinical application (1-3). Recently, the rapid development of stem cell technology has led to novel treatment methods, including the transplantation of mesenchymal stem cells (MSCs) to repair or regenerate damaged myocardium (4-7). Previous studies have demonstrated that MSCs transplanted into areas of myocardial ischemia may differentiate into myocardial cells and repair necrotic myocardial tissue. However, the effects of MSCs are insufficient, since the majority of transplanted MSCs die shortly after transplantation in the ischemic microenvironment (7,8). Therefore, a key focus of research is to improve the survival of MSCs following transplantation into ischemic tissue.

Prostaglandin E₁ (PGE₁), also termed alprostadil, is an endogenous substance, which has numerous effects, including vasodilation, protection of endothelial cells, and inhibition of the activation and aggregation of neutrophils and thrombocytes (9). Furthermore, PGE₁ is widely used in the treatment of ischemic heart disease. Clinical research has previously demonstrated the potential of PGE₁ for improving myocardial microcirculation, and counteracting the effects of ischemia-reperfusion injury and apoptosis in the myocardium (10-13). These findings indicate that PGE₁ may have a general cytoprotective action; however, there are currently no studies investigating whether PGE₁ may prevent apoptosis of MSCs.

Apoptosis is a type of physiological cell death, for which it is considered difficult to generate a comprehensive *in vitro* model. Serum deprivation (SD) injury *in vitro* is widely used to mimic the ischemic environment (14,15). The mitochondrial pathway is the major underlying mechanism of physiological cell death in apoptosis (16,17), and the Bcl-2 family proteins have an important role in the apoptotic response (18,19). To the best of our knowledge, the molecular

Correspondence to: Professor Yan-Qi Yang, Department of Cardiac Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107 Yanjiang West Road, Guangzhou, Guangdong 510120, P.R. China
E-mail: yanqiyang_li@yahoo.se

Key words: mesenchymal stem cells, apoptosis, serum deprivation, prostaglandin E₁

mechanism by which PGE₁ may inhibit apoptosis of MSCs is currently unknown.

The present study established an *in vitro* model of SD-induced apoptosis, in order to explore the potential mechanisms by which PGE₁ may improve the survival of MSCs in the myocardial microenvironment following transplantation.

Materials and methods

Animals. Sprague-Dawley rats (specific pathogen free; weight, 80-100 g) of either sex were purchased from the Animal Center of Sun Yat-sen University (Guangzhou, China). All procedures of the present study were approved by the Institutional Animal Care and Use Committee of Sun Yat-sen University. The rats were maintained in 12 h light/dark cycles at a temperature of 26-26°C and with a humidity of 40-70%, with free access to a standard laboratory diet and water.

Reagents and instruments. PGE₁ was purchased from Zhuhai Schwarz Pharma Co., Ltd. (Zhuhai, China). Dulbecco's modified Eagle's medium (DMEM) and fetal bovine serum (FBS) were obtained from Gibco Life Technologies (Carlsbad, CA, USA). Penicillin-streptomycin was purchased from Solarbio Science & Technology Co., Ltd. (Beijing, China). A Hoechst 33258 Staining kit and propidium iodide (PI) were obtained from Sigma-Aldrich (St. Louis, MO, USA). Antibodies targeting Bcl-2 (cat. no. 2870), Bax (cat. no. 2772), and caspase-3 (cat. no. 9662), were purchased from Cell Signaling Technology Inc. (Danvers, MA, USA) and were used at a dilution of 1:1,000. A Bicinchoninic Acid (BCA) Protein Assay kit was purchased from Kangchen Bio-tech (Shanghai, China). Enhanced Chemiluminescence (ECL) solution was purchased from KeyGen Biotech Co., Ltd. (Nanjing, China). Fluorescein isothiocyanate (FITC)-labeled Annexin V and anti-rat CD90 (cat. no. 11-0900-81), CD45 (cat. no. 17-0461-80), CD11b/c (cat. no. 12-0110-80), and CD29 (cat. no. 46-0291-80), antibodies were purchased from BD Biosciences (San Jose, CA, USA).

Cell preparation and culture. MSCs were isolated from the femora and tibiae of Sprague Dawley rats, which had been sacrificed by cervical dislocation. The cells were cultured in DMEM supplemented with 10% FBS and penicillin-streptomycin (50 U/ml), and were incubated at 37°C in a humidified atmosphere containing 5% CO₂. The culture medium was refreshed every 2-3 days. Each primary culture was passaged 1:2 once the MSCs had grown to 80% confluence. MSCs at passage 4, which were positive for CD90 and CD29, and negative for CD45 and CD11b/c, were collected and used for subsequent experiments.

SD-induced apoptosis. The MSCs were randomly divided into three groups and cultured for 24 h. The control group was cultured with complete medium supplemented with 10% FBS; the SD group was cultured with SD medium; and the PGE₁+SD group was cultured with SD medium plus 10 ng/ml PGE₁.

Hoechst 33342 staining. The culture medium was discarded, and the cells were washed three times with phosphate-buffered

saline (PBS), and fixed in 4% paraformaldehyde for 15 min at room temperature. The fixing solution was then discarded and the cells were washed with PBS for 5 min and incubated in Hoechst 33342 in the dark for 15 min at room temperature. Following the 15 min incubation, the Hoechst 33342 solution was discarded, and the cells were washed for a further 5 min with PBS. The cells were then supplemented with PBS and observed under an inverted fluorescence microscope (Olympus, Tokyo, Japan). The apoptotic cells exhibited morphological changes, including shrinkage and condensed nuclei.

Flow cytometric (FCM) analysis of apoptosis. The MSCs from passage 4 were digested with 0.05% Trypsin-EDTA (Gibco Life Technologies) for 5 min at 37°C, resuspended at a concentration of 10x10⁵ cells/ml and centrifuged at 300 x g for 5 min. Following centrifugation, the cells were collected in PBS at 4°C, washed twice, and resuspended in 100 ml binding buffer (BD Biosciences). In a 5 ml dry flow tube the cells were added to 5 µl Annexin V-FITC (BD Biosciences) and 5 µl PI (BD Biosciences), lightly vortexed, and incubated in the dark at room temperature for 15 min. Following incubation, 400 µl binding buffer was added, and the flow tube was placed on ice. PI and Annexin V-FITC fluorescence was measured using a flow cytometer (BD FACSVerse; BD Biosciences; excitation, 488 nm; emission, 615 nm). The research software (BD FACSsuite software; BD Bioscience) matched with FCM was used to analyze the data. Positive Annexin V staining indicated apoptosis, and positive PI staining indicated necrosis. The experiment was repeated three times.

Western blot analysis of Bcl-2, Bax and caspase-3. The MSCs were seeded into a 60 mm petri dish, at a density of 10x10⁵ cells/dish. The total protein was extracted using radio-immunoprecipitation buffer (EMD Millipore), supplemented with PMSF. The cells were sonicated briefly and centrifuged at 10,000 x g at 4°C. The protein concentration was measured using the BCA Protein Assay kit, according to the manufacturer's instructions. Equal samples of protein (20 µg) were separated by 12% SDS-PAGE and then transferred onto polyvinylidene difluoride membranes (EMD Millipore, Billerica, MA, USA). The membranes were incubated with blocking solution (Beyotime Institute of Biotechnology, Jiangsu, China) at room temperature for 2 h, and then incubated with the following primary antibodies: Bcl-2, Bax, caspase-3 and GAPDH (cat. no. KC-5G5; KangChen Biotech, Shanghai, China; dilution, 1:10,000) at 4°C overnight. The membranes were then incubated for 1 h at room temperature with the appropriate horseradish peroxidase conjugated-secondary antibodies. The blots were visualized using an enhanced chemiluminescence solution (EMD Millipore) and were exposed to X-ray film (Kodak, Tokyo, Japan). The density of the protein bands was analyzed using ImageJ 1.41 software (National Institutes of Health, Bethesda, MD, USA). The expression levels of the target proteins were normalized to those of GAPDH.

Statistical analysis. The data are expressed as the mean ± standard deviation. Comparisons between the groups were analyzed by one-way analysis of variance or Student's t-test. Statistical analyses were performed using SPSS 16.0 (SPSS,




Figure 1. Morphology of MSCs at passage 4. (A) Control, untreated MSCs; (B) SD, serum-deprived MSCs; (C) SD+PGE₁, serum-deprived MSCs cultured with 10 ng/ml PGE₁. Image visualized under a phase-contrast microscope (magnification, x100). MSC, mesenchymal stem cells; Con, control; SD, serum deprived; PGE₁, prostaglandin E₁.

Inc., Chicago, IL, USA). $P < 0.05$ was considered to indicate a statistically significant difference.

Results

MSC morphology and identification. MSCs were isolated and expanded from Sprague Dawley rats. The control MSCs were shown to sparsely attach to the culture flasks, and the majority of cells displayed a spindle-like shape (Fig. 1A). In the MSCs cultured with SD medium cells did not display the typical spindle-like shape, and a large number of floating dead cells were observed (Fig. 1B). Following treatment with PGE₁, the morphology of the MSCs cultured with SD changed, and the number of floating dead cells was reduced, as compared with the cells cultured with SD alone (Fig. 1C). The MSCs at passage 4 were stably positive for CD90 and CD29 markers, and negative for CD45 and CD11b/c markers.

PGE₁ inhibits SD-induced apoptosis. Hoechst 33342 staining showed that the majority of the MSCs in the control group were round or oval-shaped, and had light-blue regular nuclei (Fig. 2A). In the PGE₁+SD group, the apoptotic cells were round or oval-shaped, with bright-blue irregular nuclei, which indicated chromosome condensation. The number of apoptotic cells in the SD group was significantly increased, as compared with the control group. Treatment with PGE₁ significantly reduced the rate of MSC apoptosis, as compared with the SD group. Furthermore, flow cytometry of Annexin V/PI-stained cells was used to quantify the apoptotic rate of the MSCs. The percentage of apoptotic cells was significantly higher in the SD ($P < 0.01$) and SD+PGE₁ ($P < 0.05$) groups, as compared with the control group (Fig. 2B and C). In addition, the rate of apoptosis was lower in the PGE₁-treated MSCs, as compared with the untreated MSCs cultured with SD ($P < 0.05$).

SD influences the expression levels of apoptosis-associated proteins Bax, Bcl-2 and caspase-3. The present study determined whether SD could affect the expression levels of the proapoptotic Bcl-2 family members, Bax and Bcl-2. Western blot analysis showed that the protein expression levels of Bax were significantly increased and the protein expression levels of Bcl-2 gradually decreased, following exposure to SD for 12-24 h (Fig. 3A and B). Cleaved caspase-3 expression was

not detected in the control MSCs, however its expression was significantly increased in the MSCs cultured in SD medium (Fig. 3C).


Effects of PGE₁ on the protein expression levels of Bax, Bcl-2 and caspase-3. Treatment with PGE₁ significantly reduced SD-induced Bax protein expression levels and increased the protein expression levels of Bcl-2 (Fig. 4A). PGE₁ also reduced the protein expression levels of cleaved caspase-3 in the MSCs (Figure 4B). These results indicate that PGE₁ was able to attenuate SD-induced apoptosis through activation of Bax and deactivation of Bcl-2, thus reducing the expression of cleaved caspase-3.

Discussion


The present study reported the protective effects of PGE₁ on SD-induced apoptosis in MSCs, and this effect was shown to be mediated through the mitochondrial caspase-3 pathway. The results of the present study demonstrated that treatment with PGE₁ (10 ng/ml) decreased SD-induced apoptosis in MSCs, as shown by Hoechst 33342 staining, flow cytometry and measurement of caspase-3 protein expression levels. Furthermore, PGE₁ protected MSCs against SD-induced apoptosis by downregulating Bax expression and upregulating Bcl-2 expression.

MSCs are non-hematogenic stem cells, which are present in the bone marrow. Due to their availability, potential for differentiation (20) and amplification, and association with fewer ethical issues (21), MSCs have become a focus of attention in the field of experimental and clinical research regarding myocardial regeneration. However, the ischemic cardiac microenvironment reduces the survival rate of transplanted cells, and limits their therapeutic effects (22). More than 90% of MSCs have previously been shown to die within 24 h of transplantation (23). Another study demonstrated that only ~21% of MSCs survive after 4 h of transplantation, and only 3.6% survive seven days (24). To address the problem of poor survival, research has focused on strategies that inhibit apoptosis of MSCs and improve their therapeutic effects in the ischemic myocardium. Such strategies include the use of genetically modified stem cells, preconditioning of stem cells, and combination drug therapy prior to transplantation of the

A



B



C




Figure 2. Apoptosis of MSCs exposed to serum deprivation with or without PGE₁ preconditioning. (A) Morphological changes to the apoptotic cells were assessed by Hoechst 33258 staining (magnification, x100). Control, untreated MSCs; SD, serum-deprived MSCs; SD+PGE₁, serum-deprived MSCs cultured with 10 ng/ml PGE₁. MSCs were incubated for 24 h. (B) Flow cytometric analysis of the influence of 10 ng/ml PGE₁ on SD-induced apoptosis. Apoptotic cells were identified by Annexin V and PI staining; viable cells are Annexin V⁻/PI⁻, early apoptotic cells are Annexin V⁺/PI⁻, late apoptotic cells are Annexin V⁺/PI⁺, and necrotic cells are Annexin V⁻/PI⁺. (C) The results show that 10 ng/ml PGE₁ reduced apoptosis of MSCs after 24 h of serum deprivation. The data are presented as the mean ± standard error (n=5). **P<0.01, as compared with the control group; #P<0.05, as compared with the SD group. MSC, mesenchymal stem cells; Con, control; SD, serum deprived; PGE₁, prostaglandin E₁; PI, propidium iodide.

cells into the damaged myocardium (25). Genetic modification (26,27) and preconditioning (28) of MSCs may improve the survival rate of stem cells; however, these are difficult to perform clinically. Whereas, combination drug therapy improves the viability of MSCs and is convenient for clinical application. Zhang *et al* (29) previously used rosuvastatin as a combination therapy to improve the therapeutic efficacy of MSCs for treating myocardial infarction. Furthermore, Dong *et al* (30) used combination therapy with atorvastatin, which was shown to activate AMP-activated protein kinase (AMPK); phosphorylation of AMPK resulted in activation of

endothelial nitric oxide synthase. This mechanism may also be associated with the protection of MSCs against SD-induced apoptosis, through the mitochondrial apoptosis signaling pathway.

PGE₁ is widely used in the treatment of ischemic heart disease. Previous research has identified the ability of PGE₁ to improve myocardial microcirculation, reduce ischemic-reperfusion injury, and exert anti-inflammatory and antiapoptotic effects on the myocardium (10-13,31). PGE₁ also exhibits general cytoprotective effects and anti-apoptotic activity (32). It has previously been reported that PGE₁ is able to significantly




Figure 3. Protein expression levels of Bcl-2, Bax and caspase-3 in MSCs, as determined by western blotting following 12, 24 and 48 h of serum deprivation. Protein expression levels of (A) Bcl-2, (B) Bax and (C) cleaved caspase-3. GAPDH was used as a loading control, and the expression levels of the target proteins were determined relative to the levels of GAPDH. Blots shown are from \geq three independent experiments. The data are presented as the mean \pm standard error (n=5). *P<0.05 and **P<0.01, as compared with the control group. MSCs, mesenchymal stem cells; Con, control; SD, serum deprived.




Figure 4. Western blot analysis of Bax, Bcl-2 and caspase-3 following 24 h of serum deprivation with or without PGE₁ preconditioning. Control, untreated MSCs; SD, serum-deprived MSCs; SD+PGE₁, serum-deprived MSCs cultured with 10 ng/ml PGE₁. MSCs were cultured at 37°C in a humidified atmosphere containing 5% CO₂. Protein expression levels of (A) Bax and Bcl-2, and (B) caspase-3. GAPDH was used as a loading control, and the expression levels of the target proteins were determined relative to the levels of GAPDH. Blots are shown from at least three independent experiments. The data are presented as the mean \pm standard error (n=5). *P<0.01, as compared with the control group; #P<0.05, **P<0.01, as compared with the SD group. MSC, mesenchymal stem cells; Con, control; SD, serum deprived; PGE₁, prostaglandin E.

upregulate antiapoptotic proteins, such as Bcl-2 (33); and downregulate Bax and caspase-3 (13). The present study established an *in vitro* SD-induced apoptosis model, in order to explore the potential mechanisms for the protective effects of PGE₁ on MSCs. Apoptosis was detected by Hoechst 33258 and Annexin V-FITC/PI double staining. PGE₁ was shown to protect the MSCs against SD-induced apoptosis. However, apoptosis involves a series of gene activation, expression

and regulation; therefore, further investigation is required to explore the underlying molecular mechanisms by which PGE₁ inhibits apoptosis of MSCs.

The Bcl-2 family is an important apoptosis-regulating family, which includes the antiapoptotic molecule Bcl-2 and proapoptotic molecule Bax (34). Numerous studies have demonstrated that Bcl-2 and Bax are associated with the mitochondrial membrane (35-39). Bcl-2 is predominantly localized to endoplasmic reticulum and mitochondrial membranes, where it prevents the release of cytochrome *c* from the mitochondria and inhibits glutathione leakage, thus blocking programmed cell death (40,41). Bcl-2 can inhibit the activation of caspases, including caspase-9 and caspase-3, and thereby acts as an antiapoptotic agent (42). Bax is predominantly localized to the cytosol, or may be loosely attached to the mitochondrial membrane in an inactive form in healthy cells. Apoptotic stimuli result in structural changes to Bax, which may facilitate the translocation of Bax from the cytosol to the mitochondria, leading to apoptosis (43). Bax exhibits extensive amino acid homology with Bcl-2, and can form homodimers and heterodimers with Bcl-2 *in vivo* (44). The overexpression of Bax counteracts the death repressor activity of Bcl-2, and the activation of caspase-3 is dependent on the ratio of Bcl-2 to Bax, which controls cell survival and death following an apoptotic stimulus (44,45). Caspase-3 is a critical mediator of mitochondrial apoptosis (46), which can be activated by SD in MSCs (47).

The effects of PGE₁ on the inhibition of caspase-3 and regulation of Bcl-2 and Bax have previously been reported (13,33,48); however, the present study is the first, to the best of our knowledge, to report such effects in MSCs. To confirm these findings, western blot analysis was used to detect the protein expression levels of Bax, Bcl-2 and caspase-3. SD downregulated the protein expression levels of Bcl-2, and upregulated the expression levels of Bax in MSCs, resulting in overexpression of caspase-3, which caused an increased rate of MSC apoptosis. Furthermore, treatment with PGE₁ significantly increased the expression levels of Bcl-2 and inhibited the expression levels of Bax and caspase-3, thereby attenuating apoptosis in MSCs. Apoptosis is a complex process, and the SD model used in the present study attempted to simulate the myocardial microenvironment *in vitro*. However, further investigation is required to confirm these findings *in vivo*.

In conclusion, the results of the present study demonstrated that PGE₁ exerts protective effects against SD-induced MSC apoptosis. PGE₁ downregulated the protein expression levels of Bax and caspase-3, and upregulated the protein expression levels of Bcl-2 in the SD *in vitro* model. These findings may be useful in the clinical application of PGE₁ alongside MSC transplantation into ischemic tissue, and may enhance the efficacy of cell therapy.

Acknowledgements

The authors of the present study would like to thank Dr Run-min Guo, Professor Hong-fu Wu and Dr Qing-feng Xiang for technical assistance. This study was supported by the program of 'One Hundred Talented Scholars' of Sun Yat-sen University (grant no. F002009011).

References

1. Yu Q, Fan W and Cao F: Mechanistic molecular imaging of cardiac cell therapy for ischemic heart disease. *Am J Physiol Heart Circ Physiol* 305: H947-H959, 2013.
2. Toyoda Y, Guy TS and Kashem A: Present status and future perspectives of heart transplantation. *Circ J* 77: 1097-1110, 2013.
3. Burchill LJ and Ross HJ: Heart transplantation in adults with end-stage congenital heart disease. *Future Cardiol* 8: 329-342, 2012.
4. Schächinger V, Erbs S, Elsässer A, *et al*: Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. *Eur Heart J* 27: 2775-2783, 2006.
5. Tse HF, Thambar S, Kwong YL, *et al*: Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial). *Eur Heart J* 28: 2998-3005, 2007.
6. Strauer BE and Steinhoff G: 10 years of intracoronary and intramyocardial bone marrow stem cell therapy of the heart: from the methodological origin to clinical practice. *J Am Coll Cardiol* 58: 1095-1104, 2011.
7. Tang YL, Tang Y, Zhang YC, Qian K, Shen L and Phillips MI: Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. *J Am Coll Cardiol* 46: 1339-1350, 2005.
8. Menasché P: Current status and future prospects for cell transplantation to prevent congestive heart failure. *Semin Thorac Cardiovasc Surg* 20: 131-137, 2008.
9. Zhao XS, Pan W, Bekeredjian R and Shohet RV: Endogenous endothelin-1 is required for cardiomyocyte survival *in vivo*. *Circulation* 114: 830-837, 2006.
10. Fang WT, Li HJ and Zhou LS: Protective effects of prostaglandin E1 on human umbilical vein endothelial cell injury induced by hydrogen peroxide. *Acta Pharmacol Sin* 31: 485-492, 2010.
11. Takikawa M, Sumi Y, Tanaka Y, *et al*: Protective effect of prostaglandin E₁ on radiation-induced proliferative inhibition and apoptosis in keratinocytes and healing of radiation-induced skin injury in rats. *J Radiat Res* 53: 385-394, 2012.
12. Li JH, Yang P, Li AL, Wang Y, Ke YN and Li XL: Cardioprotective effect of liposomal prostaglandin E1 on a porcine model of myocardial infarction reperfusion no-reflow. *J Zhejiang Univ Sci B* 12: 638-643, 2011.
13. Jia C, Dai C, Bu X, *et al*: Co-administration of prostaglandin E1 with somatostatin attenuates acute liver damage after massive hepatectomy in rats via inhibition of inflammatory responses, apoptosis and endoplasmic reticulum stress. *Int J Mol Med* 31: 416-422, 2013.
14. Zeng X, Yu SP, Taylor T, Ogle M and Wei L: Protective effect of apelin on cultured rat bone marrow mesenchymal stem cells against apoptosis. *Stem Cell Res* 8: 357-367, 2012.
15. Chauvier D, Lecoq H, Langonné A, *et al*: Upstream control of apoptosis by caspase-2 in serum-deprived primary neurons. *Apoptosis* 10: 1243-1259, 2005.
16. Chalah A and Khosravi-Far R: The mitochondrial death pathway. *Adv Exp Med Biol* 615: 25-45, 2008.
17. Suen DF, Norris KL and Youle RJ: Mitochondrial dynamics and apoptosis. *Genes Dev* 22: 1577-1590, 2008.
18. Martinou JC and Youle RJ: Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. *Dev Cell* 21: 92-101, 2011.
19. Gross A, McDonnell JM and Korsmeyer SJ: BCL-2 family members and the mitochondria in apoptosis. *Genes Dev* 13: 1899-1911, 1999.
20. Zhang X, Wang Y, Gao Y, *et al*: Maintenance of high proliferation and multipotent potential of human hair follicle-derived mesenchymal stem cells by growth factors. *Int J Mol Med* 31: 913-921, 2013.
21. Ding DC, Shyu WC and Lin SZ: Mesenchymal stem cells. *Cell Transplant* 20: 5-14, 2011.
22. Hale SL, Dai W, Dow JS and Kloner RA: Mesenchymal stem cell administration at coronary artery reperfusion in the rat by two delivery routes: a quantitative assessment. *Life Sci* 83: 511-515, 2008.
23. Hodgetts SI, Beilharz MW, Scalzo AA and Grounds MD: Why do cultured transplanted myoblasts die *in vivo*? DNA quantification shows enhanced survival of donor male myoblasts in host mice depleted of CD4+ and CD8+ cells or Nk1.1+ cells. *Cell Transplant* 9: 489-502, 2000.

24. Tang YL, Tang Y, Zhang YC, Qian K, Shen L and Phillips MI: Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. *J Am Coll Cardiol* 46: 1339-1350, 2005.
25. Mingliang R, Bo Z and Zhengguo W: Stem cells for cardiac repair: status, mechanisms and new strategies. *Stem Cells Int* 2011: 310928, 2011.
26. Huang J, Zhang Z, Guo J, *et al*: Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium. *Circ Res* 106: 1753-1762, 2010.
27. Huang F, Zhu X, Hu XQ, *et al*: Mesenchymal stem cells modified with miR-126 release angiogenic factors and activate Notch ligand Delta-like-4, enhancing ischemic angiogenesis and cell survival. *Int J Mol Med* 31: 484-492, 2013.
28. Liu XB, Chen H, Chen HQ, *et al*: Angiopoietin-1 preconditioning enhances survival and functional recovery of mesenchymal stem cell transplantation. *J Zhejiang Univ Sci B* 13: 616-623, 2012.
29. Zhang Z, Li S, Cui M, *et al*: Rosuvastatin enhances the therapeutic efficacy of adipose-derived mesenchymal stem cells for myocardial infarction via PI3K/Akt and MEK/ERK pathways. *Basic Res Cardiol* 108: 333, 2013.
30. Dong Q, Yang Y, Song L, Qian H and Xu Z: Atorvastatin prevents mesenchymal stem cells from hypoxia and serum-free injury through activating AMP-activated protein kinase. *Int J Cardiol* 153: 311-316, 2011.
31. Huang CL, Wu YW, Wang SS, *et al*: Continuous intravenous infusion of prostaglandin E1 improves myocardial perfusion reserve in patients with ischemic heart disease assessed by positron emission tomography: a pilot study. *Ann Nucl Med* 25: 462-468, 2011.
32. Hara Y, Akamatsu Y, Maida K, *et al*: A new liver graft preparation method for uncontrolled non-heart-beating donors, combining short oxygenated warm perfusion and prostaglandin E1. *J Surg Res* 184: 1134-1142, 2013.
33. Ma XQ, Fu RF, Feng GQ, Wang ZJ, Ma SG and Weng SA: Hypoxia-reoxygenation-induced apoptosis in cultured neonatal rat cardiomyocytes and the protective effect of prostaglandin E. *Clin Exp Pharmacol Physiol* 32: 1124-1130, 2005.
34. Dietrich JB: Apoptosis and anti-apoptosis genes in the Bcl-2 family. *Arch Physiol Biochem* 105: 125-135, 1997 (In French).
35. Renault TT, Teijido O, Antonsson B, Dejean LM and Manon S: Regulation of Bax mitochondrial localization by Bcl-2 and Bcl-x(L): keep your friends close but your enemies closer. *Int J Biochem Cell Biol* 45: 64-67, 2013.
36. Degli EM and Dive C: Mitochondrial membrane permeabilisation by Bax/Bak. *Biochem Biophys Res Commun* 304: 455-461, 2003.
37. Nemecek KN and Khaled AR: Therapeutic modulation of apoptosis: targeting the BCL-2 family at the interface of the mitochondrial membrane. *Yonsei Med J* 49: 689-697, 2008.
38. Autret A and Martin SJ: Emerging role for members of the Bcl-2 family in mitochondrial morphogenesis. *Mol Cell* 36: 355-363, 2009.
39. Garcia-Saez AJ, Fuertes G, Suckale J and Salgado J: Permeabilization of the outer mitochondrial membrane by Bcl-2 proteins. *Adv Exp Med Biol* 677: 91-105, 2010.
40. Hockenbery D, Nuñez G, Millman C, Schreiber RD and Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. *Nature* 348: 334-336, 1990.
41. Haeblerlein SL: Mitochondrial function in apoptotic neuronal cell death. *Neurochem Res* 29: 521-530, 2004.
42. Mukhopadhyay A, Shishodia S, Suttles J, *et al*: Ectopic expression of protein-tyrosine kinase Bcr-Abl suppresses tumor necrosis factor (TNF)-induced NF-kappa B activation and IkappaBalpha phosphorylation. Relationship with down-regulation of TNF receptors. *J Biol Chem* 277: 30622-30628, 2002.
43. Tan KO, Fu NY, Sukumaran SK, *et al*: MAP-1 is a mitochondrial effector of Bax. *Proc Natl Acad Sci USA* 102: 14623-14628, 2005.
44. Oltvai ZN, Millman CL and Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. *Cell* 74: 609-619, 1993.
45. Heon Seo K, Ko HM, Kim HA, *et al*: Platelet-activating factor induces up-regulation of antiapoptotic factors in a melanoma cell line through nuclear factor-kappaB activation. *Cancer Res* 66: 4681-4686, 2006.
46. Lakhani SA, Masud A, Kuida K, *et al*: Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. *Science* 311: 847-851, 2006.
47. Zhu W, Chen J, Cong X, Hu S and Chen X: Hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells. *Stem Cells* 24: 416-425, 2006.
48. Liu HJ, Ma JW, Qiao ZY and Xu B: Study of molecular mechanism of Prostaglandin E1 in inhibiting coronary heart disease. *Mol Biol Rep* 40: 6701-6708, 2013.